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Summary.-L1210 leukaemia cells were preloaded with [3H methotrexate] (MTX)
to saturate high-affinity intracellular sites, and were then incubated with [3H]MTX
to determine the steady-state intracellular MTX concentrations at extracellular
concentrations ranging from 10 ,M to zero. In addition, incubations to generate
incomplete saturation of high-affinity intracellular MTX-binding sites were also
carried out. Following determination of the total intracellular MTX, cells were
pulsed with deoxyuridine (UdR) and its incorporation into DNA examined to assess
the role of exchangeable and bound intracellular MTX on DNA synthesis. Further,
cell pellets were disrupted and dihydrofolate reductase (DHFR) activity determined
under each experimental condition. Extracellular MTX concentrations in excess of
1 uM depressed UdR incorporation to <2% of control, but incorporation rapidly
recovered to 62% of control at the point of MTX-DHFR equivalence, and exceeded
control values when all high-affinity sites were not saturated. DHFR activity was
undetectable at extracellular MTX concentrations >0-50 ,uM, and never exceeded
6 09% ofcontrol atthe "equivalence point" whereallhigh-affinity siteswere saturated.
When less than 10% of potential inhibitor sites were occupied, enzyme activity
increased rapidly, but never reached control. However, 5% of the DHFR activity was
sufficient to permit UdR incorporation to continue at 50% of control levels, and UdR
incorporation returned to control levels at20% ofthe DHFR activity. The relationship
between cellular MTX content and DNA synthesis or DHFR activity is sigmoid,
suggesting a reversible interaction between enzyme and inhibitor. This lends support
to the notion that "free" intracellular MTX is necessary for a maximal antitumour
effect, and may explain its role in "high-dose" MTX therapy in man.
RENEWED interest in the clinical utility
of MTX, occasioned by the apparent
success of "high-dose" therapy (Jaffe
et al., 1974; Mitchell et al., 1968) has
provided an impetus to re-examine its
antitumour action. Earlier investigations
(Bertino, 1963; Werkheiser, 1961) attribu-
ted this action to stoichiometric inhibition
of dihydrofolate reductase (DHFR) and
subsequent inhibition of DNA synthesis.
Recentwork, however, hassuggested arole
for intracellular MTX in excess of that
bound to high-affinity intracellular sites
("free" MTX) in achieving both maximal
suppression of DNA synthesis (Goldman,
1974; Goldman and Fyfe, 1974; Margolis
et al., 1971; Roberts and Wodinsky, 1968;
Sirotnak and Donsbach, 1974) and reduc-
tion of dihydrofolate to tetrahydrofolate
(White and Goldman, 1976). However,
the role of "free" intracellular MTX in
suppressing actual DHFR activity, and
the relationship between DHFR activity
and UdR incorporation into DNA, re-
main undefined. Moreover, the role of
DHFR-bound MTX in the absence of
"free" drug is unclear. These studies have
been undertaken to examine further the
role ofboth "free" and bound MTX on the
inhibition of DNA synthesis and on the
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activity ofDHFR in L1210 ascites tumour
in vitro.
MATERIALS AND METHODS
Chemicals.-[3', 5', 3H]MTX was obtained
from Amersham/Searle Corp., Arlington
Heights, Ill. Unlabelled MTX was obtained
from the Drug Development Branch of the
National Cancer Institute. Both drugs were
purified by linear-gradient elution with
ammonium bicarbonate buffer on a DEAE-
cellulose column as previously described
(Goldman, Lichtenstein and Oliverio, 1968).
Tritiated deoxyuridine ([6-3H] UdR, sp. act.,
21 Ci/mmol) and D-[4,5-3H]leucine (sp. act.,
1 Ci/mmol) were also obtained from Amer-
sham/Searle Corp., Arlington Heights, Ill.
Cycloheximide was obtained from the Sigma
Chemical Co., St. Louis, Mo.
Cells and media.-L1210 leukaemia cells
were grown i.p. in CDF1 female mice. Animals
were killed on Day 6 after inoculation of 105
cells, and the ascitic tumour cells harvested
by lavaging the peritoneal cavity with 4°C
bicarbonate-buffered 0.85%o NaCl (pH 7.4).
The cells were freed of red-cell contamination
by 30 sec hypotonic lysis and collected by
centrifugation at 750 g for 5 min at 4°C. The
cell pellet was resuspended in 4°C Eagle's
minimal essential medium (MEM) without
serum or folic acid, and viability assessed by
trypan-blue exclusion. All preparations had
>95% viability by this technique. Cell via-
bility was also assessed at each experimental
point by trypan-blue exclusion and found
to exceed 90%0 throughout the experimental
period.
Incubation techniques.-Thecellsuspensions
were adjusted to a cell count of 1-2 x 107/ml
and placed in glass incubation flasks suspen-
ded in a 37°C water bath and continuously
agitated by a mechanical stirrer. Before the
addition of MTX, a stream of warmed,
humidified 95% 02/5% CO2 was passed over
the incubation mixture and the mixture pre-
incubated for 5 min. MTX was then added
to give a bath concentration of 3 /tM. Follow-
ing an incubation of20 min, a period sufficient
to saturate high-affinity intracellular MTX
binding sites (Goldman et al., 1968) cells
were centrifuged at 750 g at 4°C to terminate
the incubation. The cell pellet was washed
x 2 in 4°C MEM and resuspended in a large
volume of 37°C MEM containing radio-
labelled MTX at 001, 0(05, 0 10, ()5(), 110, 3-0
and 10 /tM. The cells were then incubated for
40 min, long enough for MTX to reach a
steady state, as has been previously shown
(Goldman et al., 1968) and confirmed by
preliminary studies with this L1210 cell line.
Additional uptake studies were carried out
at an MTX concentration of 0 05 lam for a
period of up to 60 min. After uptake at 0 05
tM, cells were washed x 2 in 4°C MEM and
resuspended in a large volume of 37°C MEM
alone. MTX was allowed to efflux for 30 min.
Cells wN-ere sampled at 5 min intervals dur-
ing uptake and efflux of MTX by withdraw-
ing aliquots of cell suspension (2-4 ml) and
rapidly isolating cell pellets by centrifuga-
tion, with aspiration of the supernatant, an
aliquot of which was saved for determination
of extracellular MTX concentrations. Pellets
were wNAashed x 2 in a 4°C 0.85% NaCi solu-
tion to remove extracellular MTX, and the
resulting pellet was drawn up into a Pasteur
pipette and extruded on to a flexible poly-
ethylene disc. The cell pellet was dried over-
night at 70°C to constant weight, removed
from the oven, immediately separated from
the disc, and weighed on a Cahn RG auto-
electrobalance (Cahn Instruments, Inc., Para-
mount, Calif.). Correction for weight increases
during exposure to air at room temperature
was done by serial weight determinations and
interpolation to the time of removal from the
oven. Dry pellet weights ranged from 0-5 to
3 0 mg. The pellet was then placed in the
bottom of a scintillation vial and digested in
IN KOR at 70°C for 1 h. After cooling to
room temperature, 18 ml of a methanol-
toluene scintillation fluid (700 ml of toluene,
300 ml of methanol, 3 g of PPO, and 100 mg
ofPOPOP) were added, and the vials counted
in a Searle Analytic Mark III liquid scintilla-
tion counter (Searle Analytic, Chicago, Ill.).
The 3H-counting efficiency was 26% as deter-
mined byanexternalstandard, andthequench
variation between samples was negligible.
Deoxyuridine studies.-The incorporation
of UdR into cellular DNA was studied in a
manner similar to that described under
"Incubation Techniques", except that non-
radioactive, purified MTX was used in these
studies. After a 20 min uptake, efflux was
permitted for 40 min at all the concentrations
detailed under "Incubation Techniques",
before the addition of 50 1l of [3H]UdR to
give a final UdR concentration of 0-10 jZM.
Aliquots of cell suspension (2 ml) were then
sampled at 5 min intervals, and incubation
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terminated by the addition of 2 ml of 20%
trichloroacetic acid (TCA) at 4°C. The cells
were centrifuged into a pellet, the super-
natant aspirated and the pellet washed x 2
in 50o TCA at 4°C. Cell pellets were aspirated
into Pasteur pipettes, extruded onto poly-
ethylene discs, and processed as described
earlier. Results are expressed as mg
dry weight of the TCA precipitate. UdR
studies at an MTX concentration of 0 05 ,M
were carried out in a manner identical to
that described under "Incubation Tech-
niques". After uptake periods of 5, 10, 20, 40,
and 60 min, cells were washed x 2 and re-
suspended in 37°C MTX-free medium and
50 /il of [3H]UdR added, to give a bath
concentration of 0-10 ,M. Aliquots were then
sampled at 5 min intervals as described above.
Identical studies were carried out in the
presence of 1 mm cycloheximide, a potent
inhibitor of protein synthesis, to prevent de
novo synthesis of new DHFR during the
experimental period. Cycloheximide was in
the incubation bath during uptake, efflux,
and UdR-incorporation studies. The ability
of cycloheximide to inhibit protein synthesis
was confirmed, by studying the incorporation
of [3H]leucine into the TCA precipitate ofthe
cell suspension as described above.
A comparison between the radioactivity
recovered in the TCA precipitate and that
incorporated into DNA, as determined by
the perchlorate-extraction method (Gold-
man, 1974) revealed that >900o ofthe radio-
activity was incorporated into cellular DNA,
confirming previous reports of the reliability
of the TCA technique (Goldman, 1974).
Enzymatic studies.-Cell pellets were ob-
tained after efflux for 3 um MTX studies, and
after uptake for 0 05 .m MTX studies, to
examine the specific activity of DHFR at
pH 7. Each pellet containing 109 cells, as
measured on a Coulter Counter Model F
(Coulter Electronics, Inc., Hialeah, Fla.) was
suspended in 2-4 ml of 4°C Tris-HCl buffer
(0-05m, pH 7-0 containing 0-2m KCI). This
constituted a 1:4 dilution of the intracellular
volume, and accordingly underestimated the
effect of MTX on DHFR activity. Cells were
lysed by alternate freezing and thawing x 3
and centrifuged (27,000 g, at 4°C for 30 min).
Complete recovery of all enzyme activity
was confirmed after the third freeze-thaw
procedure (Bender and Makula, 1976). The
supernatant was recovered for assay ofDHFR
activity by a spectrophometric IlCetho(I
(Perkins et al., 1967). The assay mixture
contained in 1 ml: Tris-HCl buffer at pH 7 0,
100 ,tmol; KCI, 150 ,tmol; NADPH (Sigma
Chemical Co., St. Louis, Mo.) 01 ,tmol; and
0-05-0-2 ml of the enzyme extract. A pH of
7 0 wAas chosen as approximating to the intra-
cellular pH. The reaction was initiated by
the addition of 0 05 ,umol of dihydrofolate,
prepared from folic acid as described by
Blakley (1960) containing 10 ,umol of 2-
mercaptoethanol. Enzyme activity was deter-
mined by measuring the decrease in absor-
bance at 340 nm using a Gilford spectro-
photometer Model 2000 at 37°C. Enzyme
activity is defined as Ftmol of dihydrofolate
reduced/h/ml of enzyme extract. Alter-
natively, specific enzyme activity was deter-
mined as ,umol ofdihydrofolate reduced/h/mg
protein, as determined by the method of
Lowry et al. (1951). Concurrent controls were
run on each experimental day and results
expressed as a percent of control.
The relationship between intracellular
DHFR and tightly bound intracellular MTX
was determined by titrating the DHFR with
purified MTX as previously described (Bender
and Makula, 1976). The cell volumes used in
this analysis were calculated by determining
the cell wet and dry weights. The [14C]inulin
(New England Nuclear Corp., Boston, Mass.)
space was used to determine the extracellular
volume, as described in Goldman et al.
(1968).
RESULTS
Uptake and efflux of [3H]MTX by L1210
leukaemia
The total intracellular MTX content
under each experimental condition is
summarized in Table I. A non-exchange-
able or "tighly bound" MTX fraction of
4-27 ± 0-02 nmol/g dry cell weight was
determined. Subtracting this value from
the total intracellular MTX determined at
each extracellular MTX concentration
([MTX]e) an exchangeable intracellular
MTX value can be determined (see Table
I). Dividing this number by the ratio of
intracellular water to cell dry weight of
4-38 A 0-17 determined for this L1210
cell line, the intracellular MTX concentra-
tion ([MTX]i) can be determined. The
[MTX]i at each [MTX], are suimmarized
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TABLE I. Intracellular MTX ([MTX]e)
Concentration at Various Extracellular
Concentrations ([MTX]e)
Total
[MTX]e intracellular
(Mi) MTX
(nmol/g (try
10 28-60 X4 0.75*
3 15-23 ± 0.55*
1 9'57 ± 0.30*
0-50 7:30 -- 0-28*
0.10 4-92 ± 0-06*
0-05 4-52 ± 0.04*
0-01 4 30 ± 0-03
0 4-27 0-02
Exchangeable
intracellular [MTX]i
MTX (tim)
cell wt)
24-33 5-55
10-96 2-50
5-30 1-21
3 03 0-69
0-65 015
0-25 0-014
0(03 0-0068
O 0
Values are the means of at least, 3 experiments
performed on different (days. The exchangeable
fraction is determinedi by subtracting the noin-
exchangeable intracellulai (irug from the total
dletermined at steady statc. Dividing the exchange-
able fraction by the ratio of iintracellutlar water to
(try wt (4-38 0-17) gives [MTX]i.
* Significantly greater (P < 0.05) than the inon-
exchangeable drug level of 4-27 0-02 inmol/g dry
cell wt, as (letermine(l by paire(l t test.
in Table I. In each instance, high-affinity
intracellular sites were saturated and
"free" MTX was present in the intra-
cellular volume, with the exception of
zero [MTX]e studies.
Studies directed at subsaturation of
high-affinity intracellular sites were carried
-a
0
E
2
x
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out at a [MTX]e of 0 05 /tM. Uptake was
permitted for periods of up to 60 min, an
interval insufficient to saturate these
sites and over which uptake was linear
(Fig. 1). Efflux studies were carried out to
examine whether the intracellular MTX
level declined after these cells were washed
x 2 and resuspended in 37°C MTX-free
MEM. No significant decline in intra-
cellular MTX was observed over a 30 min
period, confirming that intracellular drug
levels were not declining during the
period of UdR incorporation studies.
Incorporation of [3H]UdR into the DNA of
LI 210 leukaemia cells
Following MTX uptake and a 40 min
efflux period, during which a steady state
was reached, cell suspensions were pulsed
with [3H]UdR and incorporation permit-
ted for a 30 min interval, over which
incorporation was linear with time. Fur-
ther, high [MTX]e did not alter the rate of
UdR entry into cells, as has been pre-
viously demonstrated in Ehrlich ascites
cells (Goldman, 1974). The UdR incorpora-
tion recorded under the experimental
conditions is summarized in Table II.
UdR-incorporation studies were also
carried out in the presence of cyclo-
heximide to prevent de novo enzyme
synthesis during the experimental period.
TABLE II. Deoxyuridine Incorporation
under Each Experimental Condition
[MTX]e
(GM)
10
3
0 5 10 20 30 40 50 60
TIME (min)
FIG. 1. MTX uiptake fron1 0-0S wui mediu1m
as afunction oftime. Afte- various intervals,
30 min is illustrated, cells wAere washed x 2
and placed in MTX-free medium to allow
efflux, and cells sampled at 10 min intervals
for 30 min (dotte(d line, open circle). Each
point represenits the mean of nt least, 3
experimenrts.
0-50
(-1(
0-05
0-01
0
0-(O x (60'
05 x 40'
0-O0 x 20'
0-05 x 10'
0-05 x 5'
UdR incorporation
(%0 of Control)
0-84
1.90
2-06
10-0
20-1
34-8
42-5
62
90
102
132
131
120
Values are the means of at least 3 experiments
on (lifferenit, days. Concurrent controls were always
incluideid with each experiment. The standard
dleviation of arny meant valtue clidl not excee(d 25%.
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A 1 mm concentration was chosen, as
preliminary studies suggested that [3H]-
leucine incorporation into the TCA pre-
cipitate of a cell suspension was inhibited
by 93% over a 60 min period of exposure,
comparable to the 20 min uptake and
40 min effiux periods used experimentally
before the addition ofUdR. Cycloheximide
decreased the absolute UdR-incorporation
rates under control and experimental
conditions below the rates in MTX-
containing cells not exposed to cyclo-
heximide. However, the relative effect of
increasing total -intracellular MTX on
UdR incorporation, as seen in Table II,
remained unaltered. The decrease ob-
served may reflect secondary inhibition of
DNA synthesis at high cycloheximide
concentrations.
Enzymatic studies
The DHFR-activity determinations in
cell homogenates after exposure to MTX,
under conditions detailed under "Uptake
and Efflux . . .", are outlined in Table III.
All activities were determined at pH 7 in
pellets of 109 cells, having an intracellular
volume of 0'60 ml, on at least 3 different
days. No DHFR activity could be detected
at an [MTX]i >1 puM, using maximum
scale expansion (0-0*10 OD units) on the
Gilford spectrophotometer, 200pl aliquots
of cell extract, excess dihydrofolate, and
observation periods ofup to 10 min. At an
[MTX]i of 0-69 uM or less, a low but
increasing level of enzyme activity was
detected with decreasing [MTX]i. When
the [MTX]i was 0 and all intracellular
high-affinity sites were saturated, the
specific activity was 6.09% of control.
This relationship is depicted graphically in
Fig. 2, where UdR incorporation and
DHFR activity were plotted against total
intracellular MTX. The [MTX]i corre-
sponding to each point is given in Table I.
Control activities varied from 0-82 to 1 07
pmol/h/mg protein on different experi-
mental days. With subsaturating quanti-
ties of MTX associated with DHFR,
enzyme activity increased to 78.7% of
control when only 16-6% of the enzyme
27
TABLE III.-Enzyme Activities at Various
Cellular MTX Levels
Total
intracellular
MTX
(nmol/g
dry cell
wt)
28-6 ± 0-75
15-2 ± 0-55
9.57 ± 030
7 30 ± 0-28
4-92 ± 006
4-52 0-06
4-30 ± 003
4-27 ± 0-02
3-38 0-11
2-57 ± 005
1-28 ± 0 04
0-71 ± 0-02
037 ± 0-02
DHFR sp. act.
(j,mol/h/mg
protein)
0 ±0
0 ±0
0 ±0
0-0202 ± 0 003
0-0233 ± 0-005
0 0405 ± 0-006
0 0454 ± 0 007
0 055 ± 0-011
0-12 ± 0.01
0-21 ± 0-01
0-51 ± 0-14
0-78 ± 0-11
0-76 ± 0-11
DHFR activity
(% ofcontrol)
0 ±0
0 ±0
0 ±0
2-07 ± 0-21
2-55 ± 0-17
4-43 ± 0-14
4.97 ± 0-06
6-09 ± 1-49
12-2 ± 0-62
21-5 ± 1-5
51.1 ± 90
78-7 ± 2-7
76-6 ± 2-5
Enzyme activities are the means ± s.d. of
duplicate determinations of enzyme activity in cell
pellets of 109 cells prepared on at least 3 different
experimaental days. Concurrent controls were run
on each experimental day. Total [MTX]i represents
the mean ± s.e. of at least 3 experiments on
different days.
sites (assuming a 1:1 MTX to DHFR
association) were saturated. UdR incor-
poration was enhanced to 130% or more
of control at these same points, (Figs. 2
and 3). The recovery of DNA synthesis is
seen to occur concurrently with, but at a
slower rate than, the recovery of DHFR
activity. Maximal suppression of both
DHFR activity and UdR incorporation
appears to require "free" intracellular
MTX. Conversely, both DHFR activity
and UdR incorporation rapidly recovered
and approached or exceeded control
values, as fewer high-affinity sites were
MTX-associated. When DHFR activity
was undetectable, minimal UdR incor-
poration was still found (Fig. 2). However,
when the DHFR activity recovered to
5% of control, UdR incorporation recov-
ered to 50% of control, reaching 100%
when DHFR activity was 20% of control
(Fig. 3).
The relationship between high-affinity
intracellular MTX and DHFR was exam-
ined by determing the J5o values for MTX,
and converting this amount of drug to
,umol ofDHFR/g dry cell wt, using modifi-
cations of a previously described method
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FIG. 2.-UdR incorporation into DNA and DHFR activity at various total intracellular MTX
contents. Each point represents the mean value of at least 3 experiments performed on different
days. All points to the right of the vertical arrow represent total intracellular MTX in excess of
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FIG. 3.-The relationship between DHFR
activity and UdR incorporation. The
points are derived from data in Fig. 2.
(Bender and Makula, 1976). The '50 to
l0OO conversion required no modification,
but our cell wet wt/dry wt ratio of
5-23 ± 0 49 required alteration of the
cell number to dry wt conversion from
that previously published (Bender and
Makula, 1976). This method generated a
mean DHFR content of3-87 ± 0-41 ,mol/
g dry cell wt compared to a non-exchange-
able MTX content of 4-27 ± 0-02 ,umol/g
dry cell wt. These values do not differ
significantly by paired t test, confirming
that the non-exchangeable MTX level
corresponds to the cellular DHFR content.
DISCUSSION
Methotrexate traverses the cell mem-
branes of L1210 cells by an active trans-
port mechanism (Goldman et al., 1968) and
accumulates in the intra-cellular space in
at least 2 states. A constant amount
appears bound to DHFR, and a variable
408
u409 METHOTREXATE-DIHYDROFOLATE REDUCTASE INTERACTION
quantity ("free" MTX) accumulates in
excess of the bound amount. The role of
both bound and "free" MTX has been
examined herein. It has been shown in
vitrothat "free" drugisrequired maximally
to suppress UdR incorporation into DNA
and DHFR activity required for the
reduction of dihydrofolate to tetrahydro-
folate, a cofactor essential for 1-carbon
metabolism. This observation is in agree-
ment with the in vitro work of Goldman
(1974), Whiteand Goldmana(1976), Roberts
and Wodinsky (1968), Sirotnak and Dons-
bach (1974), and Borsa and Whitmore
(1969). These investigators have reported
maximal inhibitory [MTX]e of 3, 30, 0 9
and 1-0 Hm, respectively, in several mam-
malian tumour cell lines. Sirotnak and
Donsbach (1974) have expanded this
view, by observing that less intracellular
MTX was required in vivo to achieve the
same effect, and observed that about
120 min of MTX exposure was required to
achieve maximal suppression of UdR
incorporation. However, inspection of
their data reveals that 9000 or more
inhibition was already found by 60 min of
exposure, the experimental period used
in our studies. They conclude that the
role of exchangeable intracellular drug
may be to titrate MTX which slowly
dissociates from DHFR binding.
The direct measurement of DHFR
activity may circumvent the potential
artifact introduced by the delayed effect of
MTX on UdR incorporation. These studies
require cell-free preparations, dihydro-
folate concentrations in excess of those
achieved physiologically, and a dilution of
the intracellular volume. Accordingly,
they are likely to underestimate the effect
of a given [MTX]i on enzyme activity.
Moreover, as the MTX concentration is
static in these studies, and not subject to
half-life decay and distribution pharmaco-
dynamics as in an intact organism, this
system may be a poor model for study of
the in vivo interaction between MTX and
DHFR in the intact cell. However,
attemptin(g to take these problems into
account, our(data reveal that UdR
incorporation declines from 610% ofcontrol
at the "equivalence point" where all high-
affinity sites are saturated to 0.89% of
control at a [MTX]e of 10 pM. However,
DHFR activity drops to a less but
statistically significant degree, from 6 09%
of control at the "equivalence point" to
zero at an [MTX]e or 1 juM or greater. The
significance of this 6% change in DHFR
activity remains speculative, but may be
fundamental to the role of exchangeable
intracellular MTX. If 6% of the enzyme
activity is sufficient to support cellular
functions, "free" MTX may be needed
for maximal cytotoxicity. Conversely, if
the 6% activity is insufficient for cell
maintenance, only saturation of all high-
affinity intracellular binding sites is needed
for a maximal MTX effect. As 5% of the
DHFR activity is sufficient to permit UdR
incorporation to continue at 50% of
control levels (Fig. 3) there is reason to
suspect that "free" MTX is necessary. If,
indeed, the MTX-DHFR association is
slowly reversible, kinetic considerations
would dictate that maximal inhibition of
enzyme activity requires "free" drug in
the intracellular fluid to keep all the
enzyme sites saturated. Thus, although a
Ki of the order of 10-10 has been reported
for MTX-DHFR in cell-free preparations
(Bertino et al., 1964; Werkheiser, 1961)
for reductases from several sources, in-
ability to determine this value in the
intact cell poses a problem. A significant
dissociation rate for MTX would explain
the necessity for exchangeable intra-
cellular drug. This view is consistent with
the sigmoid relationship between total
intracellular MTX and DHFR activity or
UdR incorporation rates (Fig. 2). Such a
curve is most compatible with a slowly
reversible enzyme-inhibitor interaction in
which some, but not all, inhibitor is
enzyme bound (Straus and Goldstein,
1943). Whereas study of the DHFR-
MTX interaction in cell-free systems at
pH 5-9 suggests "stoichiometric" inhibi-
tion (Bertino et al., 1964) the actual
interaction occurring in the intact cell at
physiological pH is more likely to be410 R. A. BENDER AND D, M. MAKULA
slowly reversible. An alternate explana-
tion would require several forms ofDHFR
with different affinities for MTX. Although
studies by Hangg and Littlefield (1974)
suggest the existence of several species of
DHFR in MTX-resistant hamster cells,
their affinities for MTX have not been
examined, and must remain the subject of
speculation.
The likelihood of slowly reversible bind-
ing of MTX to DHFR is consistent with
the observed efficacy of "high dose" MTX
in certain human neoplasms. The low
MTX permeability of those human
tumours studied (Dedrick et al., 1975)
and inability of these cells to concentrate
MTX intracellularly (Bender, 1975) makes
them less likely to achieve "free" intra-
cellular MTX at conventional doses. Thus,
larger doses are needed to achieve higher
[MTX]e, to favour the accumulation of
"free" intracellular drug. How high an
[MTX]e must be achieved, and for how
long it must be maintained, is likely to
vary among tumours. Additional studies
in intact cells and tumours will, we hope,
provide these answers.
The authors would like to acknowledge the
excellent technical assistance of Jane M. Pitts and
James C. Drake.
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